7596-74-9

Basic information

• Product Name: 3-(1H-BENZIMIDAZOL-2-YL)ANILINE
• Synonyms: 3-(1H-benzimidazol-2-yl)aniline(SALTDATA: FREE);3-(1H-benzo[d]iMidazol-2-yl)benzenaMine;3-(1H-benzo[d]imidazol-2-yl)aniline
• CAS NO: 7596-74-9
• Molecular Formula: C₁₃H₁₁N₃
• Molecular Weight: 209.25
• Mol File: 7596-74-9.mol
• Article Data: 20

Chemical Properties

• Boiling Point: 482.5°C at 760 mmHg
• Flash Point: 277.3°C
• Appearance: /
• Density: 1.286g/cm³
• Vapor Pressure: 1.81E-09mmHg at 25°C
• Refractive Index: 1.737
• CAS DataBase Reference: 3-(1H-BENZIMIDAZOL-2-YL)ANILINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(1H-BENZIMIDAZOL-2-YL)ANILINE(7596-74-9)
• EPA Substance Registry System: 3-(1H-BENZIMIDAZOL-2-YL)ANILINE(7596-74-9)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 7596-74-9(Hazardous Substances Data)

Usage

General Description

3-(1H-benzimidazol-2-yl)aniline is a chemical compound with the molecular formula C13H11N3. 3-(1H-BENZIMIDAZOL-2-YL)ANILINE is a derivative of aniline and benzimidazole, and it is commonly used in pharmaceutical and research applications. It has the potential to be used as a building block in the synthesis of various biologically active molecules and pharmaceutical compounds. Additionally, it may have uses in the development of new materials in the field of organic chemistry. The chemical structure of 3-(1H-benzimidazol-2-yl)aniline consists of a benzimidazole ring fused to an aniline moiety, which gives it unique properties and potential reactivity in various chemical processes.

InChI:InChI=1/C13H11N3/c14-10-5-3-4-9(8-10)13-15-11-6-1-2-7-12(11)16-13/h1-8H,14H2,(H,15,16)

Upstream product

• 15456-62-9 2-(3-nitrophenyl)-1H-benzimidazole 
• 99847-32-2 3-nitro-benzoic acid-(2-nitro-anilide) 
• 99-05-8 meta-aminobenzoic acid 
• 95-54-5 1,2-diamino-benzene 
• 70086-34-9 2',3-diaminobenzanilide 
• 7647-01-0 hydrogenchloride 
• 88-74-4 2-nitro-aniline 
• 121-90-4 m-nitrobenzoic acid chloride 
• 39145-59-0 o-phenylenediamine hydrochloride 
• 99-61-6 3-nitro-benzaldehyde 
• 65953-23-3 3-nitro-N-[2-[(3-nitrobenzoyl)amino]phenyl]benzamide 
• 1709-44-0 m-aminobenzaldehyde 
• 121-92-6 3-nitrobenzoic acid 
• 5969-92-6 N-o-aminophenyl m-nitrobenzamide 

Downstream Products

• 76618-08-1 2-Methyl-3--6-bromo-quinazolin(3H)-4-one 
• 76617-99-7 2-Phenyl-3-quinazolin(3H)-4-one 
• 76618-06-9 2-Phenyl-3--6-iodo-q Quinazolin(3H)-4-one 
• 76618-04-7 2-Phenyl-3--6,8-dibromo-quinazolin(3H)-4-one 
• 76618-11-6 2-Methyl-3--6,8-dibromo-quinazolin(3H)-4-one 
• 130713-38-1 Diethyl <3-(2-benzimidazolyl)phenyl>aminomethylenemalonate 
• 76618-02-5 2-Phenyl-3--6-bromo-quinazolin(3H)-4-one 
• 849508-77-6 N-[3-(1H-benzimidazol-2-yl)-phenyl]-3-bromo-4-methoxy-benzamide 
• 477510-55-7 N-(3-(1H-benzo[d]imidazol-2-yl)phenyl)-3,4,5-triethoxybenzamide 
• 1031126-38-1 N-[3-(1H-benzimidazol-2-yl)phenyl]furan-3-carboxamide 
• 496913-64-5 N-[3-(1H-benzoimidazol-2-yl)-phenyl]-2-(2-thienyl)acetamide 
• 333395-09-8 N-[3-(1H-benzimidazol-2-yl)phenyl]-2,2-dimethylpropanamide 
• 314029-69-1 N-[3-(1H-benzimidazol-2-yl)phenyl]-3-chlorobenzamide 
• 420102-99-4 N-[3-(1H-1,3-benzodiazol-2-yl)phenyl]-3-methoxybenzamide 

Relevant articles and documents

Design and synthesis of 2-phenyl benzimidazole derivatives as VEGFR-2 inhibitors with anti-breast cancer activity

Three new series of 2-phenyl benzimidazole-based derivatives were designed, synthesized, and evaluated for their in vitro cytotoxic activity against breast cancer (MCF-7) cell lines. Three compounds 8, 9, and 15 showed high cytotoxic activities, with ICs

In vitro evaluation of the potential pharmacological activity and molecular targets of new benzimidazole-based schiff base metal complexes

Metal-based drugs, including lanthanide complexes, have been extremely effective in clinical treatments against various diseases and have raised major interest in recent decades. Hence, in this work, a series of lanthanum (III) and cerium (III) complexes, including Schiff base ligands derived from (1H-benzimidazol-2-yl)aniline, salicylaldehyde, and 2,4-dihydroxybenzaldehyde were synthesized and characterized using different spectroscopic methods. Besides their cytotoxic activities, they were examined in human U-937 cells, primate kidney non-cancerous COS-7, and six other, different human tumor cell lines: U251, PC-3, K562, HCT-15, MCF-7, and SK-LU-1. In addition, the synthesized compounds were screened for in vitro antiparasitic activity against Leishmania braziliensis, Plasmodium falciparum, and Trypanosoma cruzi. Additionally, antibacterial activities were examined against two Gram-positive strains (S. aureus ATCC 25923, L. monocytogenes ATCC 19115) and two Gram-negative strains (E. coli ATCC 25922, P. aeruginosa ATCC 27583) using the microdilution method. The lanthanide complexes generally exhibited increased biological activity compared with the free Schiff base ligands. Interactions between the tested compounds and model membranes were examined using differential scanning calorimetry (DSC), and interactions with calf thymus DNA (CT-DNA) were investigated by ultraviolet (UV) absorption. Molecular docking studies were performed using leishmanin (1LML), cruzain (4PI3), P. falciparum alpha-tubulin (GenBank sequence CAA34101 [453 aa]), and S. aureus penicillin-binding protein 2a (PBP2A; 5M18) as the protein receptors. The results lead to the conclusion that the synthesized compounds exhibited a notable effect on model membranes imitating mammalian and bacterial membranes and rolled along DNA strands through groove interactions. Interactions between the compounds and studied receptors depended primarily on ligand structures in the molecular docking study.

Benzimidazole derivative and application thereof

The invention relates to the field of medicinal chemistry, in particular to a 3-(1H-benzo [d] imidazole-2-yl) aniline derivative with alpha-glucosidase inhibition activity, and the structural generalformula of the derivative is shown in the specification.